Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 18, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 20, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001762951-26-000002
Filed / recorded
Feb 20, 2026, 11:35 PM UTC
Added to OQRO
Oct 2, 2026, 3:52 AM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
AbbVie Inc.
Issuer CIK
1551152
Ticker
ABBV
Reporting person
Nicholas Donoghoe
Relationship
Officer
Officer title
EVP, CHIEF BUS/STRAT OFFICER
Security
Common Stock, $0.01 par value
Table
Non-derivative (Table I)
Transaction date
Feb 18, 2026
Transaction code
A
Shares / units
5,172
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
81,082
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
